Maria Bensi

500 total citations
33 papers, 245 citations indexed

About

Maria Bensi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Maria Bensi has authored 33 papers receiving a total of 245 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Maria Bensi's work include Colorectal Cancer Treatments and Studies (20 papers), Cancer Genomics and Diagnostics (9 papers) and Pancreatic and Hepatic Oncology Research (8 papers). Maria Bensi is often cited by papers focused on Colorectal Cancer Treatments and Studies (20 papers), Cancer Genomics and Diagnostics (9 papers) and Pancreatic and Hepatic Oncology Research (8 papers). Maria Bensi collaborates with scholars based in Italy, United States and Canada. Maria Bensi's co-authors include Lisa Salvatore, Giampaolo Tortora, Fotios Loupakis, Matteo Fassan, Emilio Bria, Maria Alessandra Calegari, Alessandra Boccaccino, Francesca Bergamo, Giovanni Randon and Filippo Pietrantonio and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Maria Bensi

27 papers receiving 243 citations

Peers

Countries citing papers authored by Maria Bensi

Since Specialization

Citations

This map shows the geographic impact of Maria Bensi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Bensi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Bensi more than expected).

Fields of papers citing papers by Maria Bensi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Bensi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Bensi. The network helps show where Maria Bensi may publish in the future.

Co-authorship network of co-authors of Maria Bensi

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Bensi. A scholar is included among the top collaborators of Maria Bensi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Bensi. Maria Bensi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prognostic impact of Geriatric 8 and comprehensive geriatric assessment in older patients with advanced pancreatic ductal adenocarcinoma 2025 ·Journal of Geriatric Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jacopo Lenkowicz, Maria Bensi, Cinzia Bagalá, Lisa Salvatore, Giampaolo Tortora	0
2	Prognostic impact of depth of response and early tumour shrinkage in patients with BRAF^V600E-mutated metastatic colorectal cancer treated with targeted therapy 2025 ·Therapeutic Advances in Medical Oncology ·(unknown), Marco Maria Germani, Carlotta Antoniotti, Lisa Salvatore, Filippo Pietrantonio, Sara Lonardi, Maria Bensi, (unknown), Maria Alessandra Calegari, Rossana Intini, Alessandro Minelli, (unknown), (unknown), (unknown), Alberto Puccini, Daniele Lavacchi, (unknown), Massimiliano Salati, Mario Scartozzi, Chiara Cremolini	1
3	GATA6 expression in advanced pancreatic ductal adenocarcinoma (PDAC) as a prognostic and predictive biomarker in the Canadian COMPASS trial and the Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS. 2024 ·Journal of Clinical Oncology ·(unknown), Lisa Salvatore, (unknown), Yangqing Deng, Faiyaz Notta, Gun Ho Jang, Sergio Alfieri, Giuseppe Quero, Geny Piro, Carmine Carbone, Marta Chiaravalli, Maria Bensi, Cinzia Bagalá, Shawn Hutchinson, Anna Dodd, Sandra E. Fischer, Steven Gallinger, Jennifer J. Knox, Giampaolo Tortora, Grainne M. O’Kane	0
4	Treatment of patients with BRAF-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset 2024 ·ESMO Open ·Marco Maria Germani, (unknown), (unknown), Rossana Intini, (unknown), Maria Bensi, Alessandra Boccaccino, Alessandro Minelli, (unknown), (unknown), Alessandro Passardi, (unknown), Riccardo Giampieri, Mara Persano, Elisabetta Fenocchio, Alberto Puccini, Sara Lonardi, Filippo Pietrantonio, Lisa Salvatore, Chiara Cremolini	4
5	Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis 2024 ·The Lancet Oncology ·(unknown), Marta Chiaravalli, (unknown), (unknown), (unknown), Cinzia Bagalá, Maria Bensi, (unknown), (unknown), (unknown), (unknown), Emilio Bria, Giampaolo Tortora, Lisa Salvatore	12
6	The role of the multidisciplinary tumor board (MDTB) in the assessment of pancreatic cancer diagnosis and resectability: A tertiary referral center experience 2023 ·Frontiers in Surgery ·Giuseppe Quero, (unknown), Claudio Fiorillo, Roberta Menghi, Fausto Rosa, (unknown), Vito Laterza, (unknown), (unknown), Valerio Papa, Lisa Salvatore, Maria Bensi, Antonio Pio Tortorelli, Vincenzo Tondolo, Sergio Alfieri	3
7	SO-28 FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable mCRC patients: Updated and overall survival results of the phase II randomized AtezoTRIBE study 2023 ·Annals of Oncology ·Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio, Lisa Salvatore, Federica Marmorino, Margherita Ambrosini, Sara Lonardi, Maria Bensi, Roberto Moretto, (unknown), (unknown), Alessandro Passardi, Marina Grandis, Veronica Conca, (unknown), (unknown), Aurélie Catteau, Luca Boni, Jérôme Galon, Chiara Cremolini	2
8	SO-3 Clinical relevance and actionability of BRAF alterations in advanced biliary tract cancer: Preliminary results from the multicenter B-REAL study 2023 ·Annals of Oncology ·Monica Niger, Federico Nichetti, Sabina Murgioni, Valentina Zanuso, Cinzia Bagalá, Gianluca Masi, (unknown), Egle Perissinotto, Antonio De Rosa, Rita Balsano, Maria Bensi, (unknown), Giancarlo Pruneri, Lorenza Rimassa, Lisa Salvatore, Caterina Vivaldi, Francesca Bergamo, Filippo Pietrantonio, Filippo de Braud, Sara Lonardi	1
9	Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients 2023 ·Frontiers in Oncology ·Lisa Salvatore, Maria Bensi, (unknown), Ina Valeria Zurlo, Emanuela Dell’Aquila, Roberta Grande, (unknown), (unknown), Fabrizio Citarella, Maria Alessandra Calegari, (unknown), Michele A. Basso, Carmelo Pozzo, Giampaolo Tortora	0
10	P-275 FOLFOX versus FOLFIRI as second-line treatment after cisplatin-gemcitabine in patients with advanced biliary tract cancers 2023 ·Annals of Oncology ·Federico Nichetti, Mario Domenico Rizzato, Maria Bensi, Francesca Salani, (unknown), (unknown), (unknown), Marta Chiaravalli, Gianluca Masi, (unknown), (unknown), Caterina Vivaldi, Francesca Bergamo, (unknown), Maria Di Bartolomeo, Filippo de Braud, Monica Niger, Sara Lonardi	0
11	Role of Chemoradiation in the Adjuvant Treatment of Radically Resected Pancreatic Cancer Patients: A Mono-Institutional Retrospective Analysis 2022 ·Oncology Research and Treatment ·Gian Carlo Mattiucci, Lisa Salvatore, Andrea D’Aviero, Cinzia Bagalá, Maria Bensi, (unknown), Francesco Cellini, Paola De Franco, (unknown), Gabriella Macchia, (unknown), Roberta Menghi, Giuseppe Quero, (unknown), A.G. Morganti, Sergio Alfieri, Giampaolo Tortora, Vincenzo Valentini	0
12	The impact of the histological classification of ampullary carcinomas on long-term outcomes after pancreaticoduodenectomy: a single tertiary referral center evaluation 2022 ·Langenbeck s Archives of Surgery ·Giuseppe Quero, Vito Laterza, Claudio Fiorillo, Roberta Menghi, (unknown), Carlo Alberto Schena, Fausto Rosa, Antonio Pio Tortorelli, (unknown), (unknown), Maria Bensi, Lisa Salvatore, Sergio Alfieri	2
13	Management of single pulmonary metastases from colorectal cancer: State of the art 2022 ·World Journal of Gastrointestinal Oncology ·Marco Chiappetta, Lisa Salvatore, Maria Teresa Congedo, Maria Bensi, Viola De Luca, Leonardo Petracca Ciavarella, Floriana Camarda, (unknown), Vincenzo Valentini, Giampaolo Tortora, Stefano Margaritora, Filippo Lococo	16
14	Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report 2021 ·Clinical Colorectal Cancer ·Maria Alessandra Calegari, (unknown), Michele Basso, Carmine Carbone, Floriana Camarda, (unknown), (unknown), (unknown), Maria Bensi, Maurizio Martini, Carmelo Pozzo, Maria Vellone, Francesco Ardito, Lisa Salvatore, Felice Giuliante, Giampaolo Tortora	1
15	P-74 The impact of first-line chemotherapy in elderly patients with advanced pancreatic cancer: A mono-institutional retrospective study 2021 ·Annals of Oncology ·(unknown), Marta Chiaravalli, Maria Bensi, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Cinzia Bagalá, Giampaolo Tortora, Lisa Salvatore	0
16	KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population 2020 ·Clinical Colorectal Cancer ·Marta Schirripa, Floriana Nappo, Chiara Cremolini, Lisa Salvatore, Daniele Rossini, Maria Bensi, Gianluca Businello, Filippo Pietrantonio, Giovanni Randon, Giovanni Fucà, Alessandra Boccaccino, Francesca Bergamo, Sara Lonardi, Angelo Paolo Dei Tos, Matteo Fassan, Fotios Loupakis	45
17	Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis 2020 ·Clinical Colorectal Cancer ·Daniele Rossini, Marco Maria Germani, Filippo Pagani, Antonio Pellino, Emanuela Dell’Aquila, Maria Bensi, Nicole Liscia, Roberto Moretto, Alessandra Boccaccino, Michele Prisciandaro, Sara Manglaviti, Marta Schirripa, (unknown), Mario Scartozzi, Daniele Santini, Lisa Salvatore, Filippo Pietrantonio, Fotios Loupakis, Alfredo Falcone, Chiara Cremolini	15
18	Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis 2019 ·Annals of Oncology ·Daniele Rossini, Filippo Pagani, Antonio Pellino, Emanuela Dell’Aquila, Nicole Liscia, Maria Bensi, Marco Maria Germani, Gianluca Masi, Roberto Moretto, Daniele Santini, Lisa Salvatore, Mario Scartozzi, Sara Lonardi, Giulio Zucchelli, Fabio Puglisi, Francesca Vannini, (unknown), Alfredo Falcone, Filippo Pietrantonio, Chiara Cremolini	1
19	Chemotherapy rechallenge or reintroduction, regorafenib, and TAS-102 for metastatic pretreated colorectal cancer patients: a propensity score analysis of treatment beyond the second line (PROSERpINA Study) 2019 ·Annals of Oncology ·Maria Alessandra Calegari, Ina Valeria Zurlo, Michele Basso, Armando Orlandi, Maria Bensi, Floriana Camarda, (unknown), (unknown), Carmelo Pozzo, Isabella Sperduti, Emilio Bria, Lisa Salvatore, Giampaolo Tortora	1
20	Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA Study 2019 ·Annals of Oncology ·Lisa Salvatore, Maria Bensi, Filippo Pietrantonio, Alessandra Boccaccino, C. Barbara, A. Auriemma, Margherita Ratti, Emiliano Tamburini, Roberto Bordonaro, Matteo Clavarezza, Antonio Avallone, Francesca Bergamo, Cristina Granetto, Sara Bustreo, Francesca Di Fabio, Valeria Smiroldo, (unknown), Giampaolo Tortora	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact